Natco Pharma Ltd.

Natco Pharma has received tentative approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Trabectedin for Injection (generic for Yondelis ) for the 1mg/vial presentation. According to industry sales data, Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.